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context: An excess of thyroid hormone leads to a prothrombotic state, however the underlying pathophysiological mechanisms remain unknown. As evidence points towards an extensive "cross-talk" between the inflammatory and coagulation cascade, inflammation has been claimed as a possible mechanism through which different risk factors trigger venous thrombus formation. We aimed to study changes in expression of inflammation-related genes of the leukocyte RNA expression profile in healthy subjects in response to supraphysiological doses of levothyroxine.
Design and methods:
In a randomized single-blinded crossover design, twelve healthy volunteers (aged 18 to 40 years) received levothyroxine and no medication, both for 14 days with a wash-out period of at least 28 days between the periods. Blood was sampled at baseline and day 14 of each study period. MRNA was isolated from whole blood and used for multiplex ligation-dependent probe amplification to study the expression of inflammation-related genes.
Results: Compared to the control situation no significant changes were found in the expression of proinflammatory cytokines and mediators after the intake of levothyroxine.
conclusions:
The results of this study show that high thyroid hormone levels do not lead to an altered inflammatory profile. This provides evidence against a major role of the inflammatory system as mediator in the effect of thyroid hormone on the coagulation system. The mechanisms by which thyroid hormone may influence coagulation proteins remain to be elucidated.
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Since the beginning of the past century, case reports have suggested a link between thyroid dysfunction and haemostatic abnormalities (1;2). From then onwards several studies have been performed to further elucidate this relationship. An excess of thyroid hormone is thought to induce a prothrombotic state, which led to the hypothesis that hyperthyroidism is a risk factor for venous thrombosis (3). Indeed, high levels of free thyroxine (FT 4 ) are associated with an increased risk of venous thrombosis, whereas a reduced risk was found for lower levels of FT 4 (4). The underlying pathophysiological mechanisms by which thyroid hormones may influence coagulation remain ill-defined. Several mechanisms have been suggested to underlie this relation including autoimmunity, indirect effects of endothelial dysfunction and atherosclerosis, and increased peripheral sensitivity to catecholamines (5) (6) (7) (8) . Other studies have suggested a role for thyroid hormone receptor-mediated regulation of gene transcription at the hepatic and/or endothelial cell level, or both, causing an upregulation of coagulation factors (9;10).
There is increasing evidence of a "cross-talk" between the coagulation and inflammatory systems. During the last years, inflammation has been accepted as a possible mechanism through which different risk factors trigger thrombus formation (11;12) . Previous studies have investigated the relationship between the inflammatory and thyroid system, however, the results are contradictory and the interpretation was often impeded by existing concomitant diseases (13) (14) (15) . Therefore, the aim of this study was to assess whether the induction of pronounced thyroid hormone excess by suprapysiological doses of levothyroxine leads to the upregulation of inflammation-related genes in healthy volunteers.
mETHoDs study design
The effects of thyroid hormone excess on expression of inflammation-related genes were studied in a single blinded randomised crossover design. The study design
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and procedures have previously been described in detail (16) . Briefly, participants received levothyroxine or no medication for 14 days, separating each exposure period by a wash-out of at least 28 days which was chosen on the basis of the half life of levothyroxine (7 to 10 days). The order of the two periods was determined by randomization. Fasting venous blood samples were drawn at baseline and day 14 of each exposure period, at the same time of day. For safety reasons, the original study was performed in two stages (Study A and B characterized by a difference in dose of levothyroxine that was administered). The current analyses only applies to study B in which participants with a body weight below 80 kg received levothyroxine 0.45 mg per day, and levothyroxine 0.6 mg per day for those with a body weight of 80 kg and above.
Participants
Healthy volunteers aged 18 to 40 years were recruited, regardless of sex or race, by local advertisements. Volunteers were excluded if they had any of the following: history of thyroid disease or venous thrombosis, ongoing medical (especially infectious) or psychiatric illnesses, regular use of prescription or non-prescription medications including oral contraceptive agents, illicit drug use or excessive alcohol use, surgery or hospitalization in the previous 3 months, or non-traditional sleep/ wake habits (e.g. night shift work or frequent travel across time zones). Potentially eligible participants were invited for a first screening and blood sampling for routine laboratory tests (including blood count, inflammation parameters, renal, hepatic and thyroid function) was performed. In case of any significant abnormalities, volunteers were excluded from further study participation, and referred to their general physician or a specialist, if indicated.
All participants provided written informed consent. The study protocol was approved by the Medical Ethical committee of the Slotervaart Hospital.
Participants were instructed to start drug intake on day 1 of either the first or second exposure period, depending on randomization. Levothyroxine was to be taken every morning, on awakening, 30 minutes prior to ingesting any food or drinks. Participants were advised to maintain their usual sleep-wake schedule, exercise and dietary habits during the study.
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Blood collection
Fasting morning blood samples were collected in 4. 
Statistical analysis
Statistical analysis was performed using SPSS software, period. We compared baseline and day 14 levels of each expressed gene between the two exposure periods with the Wilcoxon signed ranks test. We calculated relative changes per gene for each individual by subtracting the baseline value from the day 14 value, dividing it by the baseline value and multiplying the result by 100%. We calculated the medians (95% CI) of these individual relative changes, and performed between-exposure comparisons using the Wilcoxon signed ranks test.
REsULTs
We enrolled 12 participants, 6 men and 6 woman, with a mean age of 29 (range 26-40) years. ( Table 1) . Three participants had a body weight ≥ 80 kg. whereas these values remained within the normal reference range during the control period (Table 2S) .
Median baseline values of the inflammatory markers were similar for both study periods. Table 2S shows the change in expression of inflammation-related genes.
Compared with the control situation no significant changes were found for any of the inflammation-related genes. Remarkably, although not statistically significant, we found a decreased expression of many of the inflammation related genes.
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DiscUssioN
Based on our data we conclude that supraphysiological serum levels of FT 4 was not possible due to the study design (14) . Also, discrepancies can be the result of variations in the population studied. Two studies investigated the relationship between free triiodothyronine (FT 3 ) and proinflammatory cytokines in either peritoneal dialysis patients or in patients with heart failure and compared to healthy controls. Both studies reported that low FT 3 levels were linked to an enhanced inflammatory status (13;20) . It was proposed that the increased production of different cytokines most likely originated from bone osteoblasts, although bone markers did not correlate with acute changes in thyroid hormone status after antithyroid therapy (15) .
As several studies have demonstrated a tight interplay between the coagulation and inflammatory system, different risk factors might trigger thrombus formation in veins via the inflammatory system (11). However, the question whichever comes first, inflammation or thrombus formation, is frequently brought up. It is known that the procoagulant thrombin is capable of stimulating multiple inflammatory pathways, and, inflammatory cytokines, such as interleukin (IL)-6 and IL-8 are capable of activating coagulation. One study found that elevated plasma levels of inflammatory cytokines were associated with VTE (21). The authors suggest that as these levels of inflammation markers did not differ in patients with recent VTE compared to those with more remote VTE, it is possible that the inflammatory state precedes the VTE, although this was not directly established. Two other studies, however, reported the inflammation markers measured at the time of diagnoses not to be different several days later, possibly indicating that inflammation is a consequence
rather than a cause of DVT (22;23). Despite these uncertainties surrounding the inflammation-coagulation cross-talk, we conclude that, although thyroid hormone excess has repeatedly been proven to result in a procoagulant state, it appears not to do so by an upregulation of inflammatory cytokines.
A limitation of our study is the relatively small sample size, and thus we cannot exclude that modest changes went undetected due to the small number of participants in this study. However, changes in levels of fibrinogen, von Willebrand factor, coagulation factors VIII, IX and X, and plasminogen activator inhibitor-1, were easily detectable in the same patients (16) . Also, the treatment time might not be long enough to induce changes to the inflammatory system. Finally, it is known that messengerRNA levels of inflammation related genes do not always precisely reflect amounts of proteins that are produced due to post-transcriptional regulation (18). For that reason, extrapolations of messengerRNA levels to protein levels for individual genes should be interpreted with caution. In this study, however, we did not measure plasma protein levels of inflammatory markers after the intake of levothyroxine or no medication.
In conclusion, the results of this study show that thyroid hormone excess does not lead to an altered inflammatory profile, which provides evidence against a major role of the inflammatory system as mediator in the effect of thyroid hormone on coagulation. The mechanisms by which thyroid hormone may influence coagulation proteins remain to be elucidated.
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